Clinical Trial Update: Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose maintenance peginterferon alfa-2b versus supportive care in patients with cirrhotic hepatitis C and HIV has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• Peginterferon alfa-2b (PegIntron) (peginterferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Liver Cirrhosis | Phase 3 | Status: WITHDRAWN